This case study involves a randomized Phase III study. It examined the study drug in combination with another medication versus chemotherapy in patients with checkpoint inhibitor refractory non-squamous NSCLC.
In this case study, you’ll learn:
- PRA presented a data-driven rationale for the enrollment challenges the sponsor was facing
- We did this by analyzing data intelligence assessing patterns by treatment line and utilizing our therapeutic expertise and local country standard of care knowledge
- PRA worked with the sponsor to amend the protocol to align the inclusion/exclusion criteria with treatment patterns and the usual standard of care
This study proved crucially important to leverage data intelligence and collaborate early during protocol development to ensure feasible enrollment and study success. It produced a greater number of eligible patients, higher enrollment, and a more viable country mix.
Oncology University Fact Sheet
PRA Health Sciences has responded to the industry’s urgent need to find the right CRAs for oncology research with our new Oncology University. This…
The Battle Against Leukemia and Lymphoma
A PRA Expert’s Experience Treating the First Pediatric Patient to Receive CAR T-Cell Therapy
Emily Whitehead was born on May 2nd of 2005, a perfectly healthy baby. When she reached five, her parents noticed bruising on her legs, bleeding…